



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tadalafil (Cialis & Chewtadzy) For BPH Page: 1 of 3

Effective Date: 10/6/2025 Last Review Date: 9/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Cialis (tadalafil) and Chewtadzy (tadalafil) for benign prostatic hyperplasia (BPH) under the patient's prescription drug benefit.

### Description:

#### FDA-approved Indications

#### Chewtadzy

##### **Erectile Dysfunction**

Chewtadzy is indicated for the treatment of erectile dysfunction (ED) in adult males.

##### **Benign Prostatic Hyperplasia**

Chewtadzy is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males.

##### **Erectile Dysfunction and Benign Prostatic Hyperplasia**

Chewtadzy is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH) in adult males.

#### **Limitations of Use**

If Chewtadzy is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown.

Chewtadzy is not indicated for once daily use for ED because dosing is not possible in such patients (the recommended dosage for this indication cannot be achieved with the lowest available strength).

#### Cialis

##### **Erectile Dysfunction**

Cialis is indicated for the treatment of erectile dysfunction (ED).

##### **Benign Prostatic Hyperplasia**

Cialis is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

##### **Erectile Dysfunction and Benign Prostatic Hyperplasia**

Cialis is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tadalafil (Cialis & Chewtadzy) For BPH Page: 2 of 3

Effective Date: 10/6/2025 Last Review Date: 9/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

### Limitation of Use

If Cialis is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Cialis decreases from 4 weeks until 26 weeks, and the incremental benefit of Cialis beyond 26 weeks is unknown.

### Applicable Drug List:

Chewtadzy  
Cialis  
Tadalafil

### Policy/Guideline:

#### Coverage Criteria

##### Benign Prostatic Hyperplasia (BPH)

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH)  
[Note: Examples of signs and symptoms of BPH are incomplete emptying, weak stream, straining, urinary frequency, intermittency, or urgency.]
- Inadequate response, intolerable side effects or contraindication to both of the following:
  - Two alpha blockers (for example, alfuzosin, tamsulosin, doxazosin, terazosin)
  - Finasteride for at least 6 months

#### Continuation of Therapy

##### Benign Prostatic Hyperplasia (BPH)

Authorization may be granted when the requested drug is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH) when the following criteria is met:

[NOTE: Examples of signs and symptoms of BPH are incomplete emptying, weak stream, straining, urinary frequency, intermittency, or urgency.]

- The patient has achieved or maintained a positive clinical response to the requested drug.

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tadalafil (Cialis & Chewtadzy) For BPH Page: 3 of 3

Effective Date: 10/6/2025 Last Review Date: 9/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

**Quantity Level Limit:** 30 tablets per 30 days

**References:**

1. Chewtadzy [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc. June 2024.
2. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; April 2023.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 25, 2025.
4. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/25/2025).
5. Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Part I-Initial Work-up and Medical Management. J Urol. 2021;206(4):806-817.
6. Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2023;211(1):11-19.
7. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200:633-641.
8. Ueda P, Mercer CH, Ghaznavi C, et al. Trends in Frequency of Sexual Activity and Number of Sexual Partners Among Adults Aged 18-44 Years in the US, 2000-2018. JAMA Network Open. 2020;3(6): e203833.
9. Twenge JM, Sherman RA, Wells BE. Declines in Sexual Frequency Among American Adults, 1989-2014. Arch Sex Behav. 2017;46(8):2389-2401.
10. Mark KP, Arenella K, Girard A, et al. Erectile dysfunction in the United States: report from the 2021 National Survey of Sexual Wellbeing. J Sex Med. 2024;21(4):296-303.